Arvind Chaudhry, MD
Enriched profileHematology Oncology (listed specialty) · Medical Oncology Associates
Arvind Chaudhry is Hematology Oncology (listed specialty) at Medical Oncology Associates. ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 27 Oct 2026
Overview
Updated 28 Oct 2026
Arvind Chaudhry, MD, is Hematology Oncology (listed specialty) at Medical Oncology Associates (Spokane, WA). The public record shows 80 publications with 5,094 citations (h-index 21), centered on Oncology. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 110 companies.
- Top research focus: Oncology
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 110 companies
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
Sponsor: Oral Defense, LLC
Industry payments
Updated 28 Oct 2026
110 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202526 payments
- Novartis Pharmaceuticals CorporationProgram year202535 payments
- Janssen Biotech, Inc.Program year202516 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.3%PD-1 inhibitor42.6%Pembrolizumab100%Part B, office-administered≥29 patientsKinase inhibitor0.5%Imbruvica24%Brukinsa14%Jakafi11%Cabometyx10%Calquence8%Tagrisso6%Ibrance6%Bosulif6%Verzenio5%Sprycel5%Imatinib Mesylate4%Vonjo3%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
34.8%Substance P/Neurokinin-1 Receptor Antagonist29.4%Aprepitant100%Part B, office-administered≥23 patientsSerotonin-3 Receptor Antagonist5.2%Palonosetron hcl79%Ondansetron hydrochloride19%Ondansetron Odt1%Ondansetron Hcl0%Part D + Part B<11 patients+ 3 more classes in this area
Musculoskeletal
14%RANK Ligand Inhibitor13.8%Denosumab100%Part B, office-administered≥43 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥21 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providence.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center